Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
复制标题
DOI：
10.1007/s00262-013-1475-x
复制
发表时间：
2013-11
影响因子：
5.8
通讯作者：
McCarter, Martin D.
中科院分区：
文献类型：
--
作者：
Jordan, Kimberly R.;Amaria, Rodabe N.;Ramirez, Oscar;Callihan, Eryn B.;Gao, Dexiang;Borakove, Michelle;Manthey, Elizabeth;Borges, Virginia F.;McCarter, Martin D.
晚期癌症患者外周血中髓源性抑制细胞增多；然而，没有研究表明这些免疫抑制细胞与黑色素瘤患者的临床结果相关。我们对34例IV期黑色素瘤患者、20例I期黑色素瘤患者和15名健康供者外周血中髓源性抑制细胞的多个亚群的频率和抑制功能进行了表征。IV期黑色素瘤患者外周血中CD14+ MDSCs （Lin - CD11b+ HLA-DR - CD14+ CD33+）和CD14 - MDSCs （Lin - CD11b+ HLA-DR - CD14 - CD33+）的频率相对于健康供者增加。CD14+和CD14 - MDSCs的频率相互关联，并与调节性T细胞的频率增加相关，但与传统定义的单核细胞无关。从IV期黑色素瘤患者外周血中分离的CD14−MDSCs比从健康供体中分离的CD14−MDSCs更能抑制T细胞的激活，这些细胞的频率与疾病进展和总生存期降低相关。我们的研究首次证明了CD14 - MDSCs的频率与晚期黑色素瘤患者的临床结果呈负相关。这些数据表明，抑制性MDSCs应被视为未来免疫治疗的靶点。
Myeloid-derived suppressor cells are increased in the peripheral blood of advanced-stage cancer patients; however, no studies have shown a correlation of these immunosuppressive cells with clinical outcomes in melanoma patients. We characterized the frequency and suppressive function of multiple subsets of myeloid-derived suppressor cells in the peripheral blood of 34 patients with Stage IV melanoma, 20 patients with Stage I melanoma, and 15 healthy donors. The frequency of CD14+ MDSCs (Lin− CD11b+ HLA-DR− CD14+ CD33+) and CD14− MDSCs (Lin− CD11b+ HLA-DR− CD14− CD33+) were increased in the peripheral blood of Stage IV melanoma patients relative to healthy donors. The frequency of CD14+ and CD14− MDSCs correlated with each other and with the increased frequency of regulatory T cells, but not with classically-defined monocytes. CD14− MDSCs isolated from the peripheral blood of Stage IV melanoma patients suppressed T cell activation more than those isolated from healthy donors and the frequency of these cells correlated with disease progression and decreased overall survival. Our study provides the first evidence that the frequency of CD14− MDSCs negatively correlates with clinical outcomes in advanced-stage melanoma patients. These data indicate that suppressive MDSCs should be considered as targets for future immunotherapies.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
4.4
作者：
Almand, B;Clark, JI;Gabrilovich, DI
通讯作者：
Gabrilovich, DI
影响因子：
20.3
作者：
Movahedi, Kiavash;Guilliams, Martin;Van Ginderachter, Jo A.
通讯作者：
Van Ginderachter, Jo A.
影响因子：
2.2
作者：
Kotsakis, Athanasios;Harasymczuk, Malgorzata;Schilling, Bastian;Georgoulias, Vasilis;Argiris, Athanassios;Whiteside, Theresa L.
通讯作者：
Whiteside, Theresa L.
影响因子：
11.2
作者：
Bunt, Stephanie K.;Yang, Linglin;Ostrand-Rosenberg, Suzanne
通讯作者：
Ostrand-Rosenberg, Suzanne